Boehringer Ingelheim, a family-owned pharmaceutical company, recently unveiled 15 new medicines could potentially be approved by 2025 in immunology, CNS, oncology, respiratory and cardio metabolic diseases.  

The company presented its latest pipeline updates at a recent event at its global headquarters in Ingelheim, Germany.

Boehringer Ingelheim is committing more than €20 billion ($23.3 billion) to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration.

“The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-clinical projects. Some 65 per cent of our drug pipeline candidates already have breakthrough and/or first-in-class potential, and we aim for even more” said Dr Michel Pairet, member of the Board of Managing Directors, responsible for Boehringer Ingelheim’s Innovation Unit. “Transcending disease boundaries is about looking at R&D with fresh eyes.”

To fulfil such aspirations, Boehringer Ingelheim embraces risks to dig deep into the mechanisms of diseases, to integrate the latest scientific and technological advances, and to work with the best partners to discover and deliver new medicines.

“Our worldwide team of 8,000 scientists, medical doctors and other contributors is truly motivated by our pipeline, its progress and what this could mean for patients.” commented Dr Christopher Corsico, chief medical officer, and Boehringer Ingelheim.

“With ongoing work on a first-in-class inhibitor targeting inflammatory skin and bowel diseases, transformative oncology candidates, a promising schizophrenia prevention strategy and major indications for two of our blockbusters, in lung fibrosis and in chronic kidney disease and chronic heart failure, we look forward to bringing years of health and improved quality of life to millions of people.”

To support and complement its own R&D, Boehringer Ingelheim is increasing the emphasis on external collaborations and expanding the community of innovation partners. The company currently works with over 70 innovative partners in universities, scientific institutions and biotech companies.

“Our long-lasting relationships with our partners are built on respect, empathy, trust and passion – values which foster an environment where synergies are realized, resulting in the potential for faster and better results.” said Dr Michel Pairet.  “Our long-term, unwavering commitment to researching and developing new medicines will bring the transformative medicines that patients need.”

Dr Mohamed Meshref, Boehringer Ingelheim’s medical director, Middle East, Turkey and Africa (META) said: “R&D has been the cornerstone and overall foundation of the company’s success to develop innovative medications of high therapeutic value. Across the META region, Boehringer Ingelheim has focused to introduce significant innovations in therapeutic areas that include respiratory and cardio-metabolic diseases, oncology as well as in stroke management. Our commitment to R&D is an important pillar of our growth strategy across the region.” – TradeArabia News Service